Company news
Noxopharm Ltd. (ASX:NOX) news
Noxopharm Ltd. news releases on 6ix. Latest, Mar 3, 2020: LuPIN Prostate Cancer Trial Fully Recruited
Press releases — page 4
LuPIN Prostate Cancer Trial Fully Recruited
March 2, 2020
Half Year Accounts and Chairman Letter
February 25, 2020
FDA grants IND approval to Veyonda
February 20, 2020
Noxopharm Alliance With GenesisCare
February 17, 2020
Noxopharm : LuPIN Trial Interim Results Indicate Striking Survival Benefit
February 14, 2020
$8.1M Financing & Re-Set of Capital Structure
February 13, 2020
Noxopharm Dec 2019 Appendix 4C
January 30, 2020
Listing of Nyrada Inc. spin-off on ASX
January 16, 2020
DARRT-1 Clinical Data Webinar
December 19, 2019
Nyrada IPO Offer Fully Subscribed
December 16, 2019
Lodgement of Nyrada Inc Supplementary Prospectus
December 8, 2019
Nyrada Inc Initial Public Offering Opens
December 3, 2019
Positive DARRT-1 Data in Late-Stage Prostate Cancer
December 2, 2019
Lodgement of Nyrada Inc Prospectus - Initial Public Offering
November 26, 2019
Noxopharm Announces Appointment of Chief Commercial Officer
November 6, 2019
Appendix 4C - Quarterly
October 29, 2019
Dr Graham Kelly to Assume CEO Role
October 27, 2019
Durable Anti-Cancer Effect Confirmed in DARRT-1 Study
October 20, 2019
Potential Fundamental Change in Treatment of Brain Cancer
October 17, 2019
Further Review Shows Major Clinical Benefits from Veyonda
September 30, 2019
Veyonda and Radiotherapy Profiled at Key Oncology Meeting
September 17, 2019
Appendix 4E and Audited Financial Statements FY19
August 29, 2019
More Evidence that Veyonda Enhances RT in Prostate Cancer
August 27, 2019
NOX Receives FY19 Federal Government R&D Tax Rebate
August 23, 2019
Pre-Clinical Evidence Confirms Veyonda Abscopal Effect
August 21, 2019
Noxopharm August 2019 Corporate Presentation
August 6, 2019
NOX Announces AU$26 Million Funding Facility
July 19, 2019
Conference Hears of Positive Interim Data from LuPIN Trial
June 25, 2019
Promising Data Leads to Expansion of LuPIN Trial
May 22, 2019
LuPIN Trial Demonstrates High Rates of Response
May 20, 2019
DARRT Treatment Has Lasting Disease Control at Six Months
May 2, 2019
Veyonda and Immuno-Oncology Effect Explained
April 28, 2019
Idronoxil Confirmed as New Immuno-Oncology Drug
April 16, 2019
Veyonda Chemotherapy Enhancement Program to be Expanded
April 9, 2019
KZA: Kazia sells stake in Noxopharm
March 19, 2019
Noxopharm to expedite Veyonda Clinical Program
February 20, 2019
FNN interview with Nox Chief Medical Officer on Interim Data
February 6, 2019
Veyonda and Radiotherapy Delivers Clinical Benefits
February 5, 2019
Principal Investigator Discusses LuPIN-1 Study
January 13, 2019
NOX Receives $3.26M Federal Govt R&D Rebate
December 20, 2018
DARRT-1 study advancing on basis of positive clinical data
December 10, 2018
NOX announces Positive Data from CEP-1 Study of Veyonda
November 28, 2018
NOX to Present Clinical Data at COSA Annual Meeting
November 12, 2018
Appendix 4C - quarterly
October 25, 2018
Change of Registry Address: Automic P/L - Sydney Office
September 28, 2018
NOX Subsidiary Announces Important Drug Discovery
September 24, 2018
NOX to support expanded LuPIN study
September 4, 2018
Nyrada-Key progress with cholesterol-lowering drug candidate
August 26, 2018
VEYONDA - Registered Trade Mark for NOX66
August 20, 2018
Release of DARRT-1 Preliminary Safety Data
July 8, 2018